ImmunGene is a privately held drug discovery and
development company, developing next generation of monoclonal antibody-based therapeutics to treat cancer,
autoimmune disorders and other diseases.
ImmunGene is working to make our novel drug
candidates for treating diseases that affect tens
of millions of people worldwide. ImmunGene's primary focus is on safe
and effective treatments for cancer.
ImmunGene also has programs underway to treat other potentially devastating
diseases, including infections.
leveraging promising science to tap the power of the immune systems to
develop therapeutic antibodies that are highly optimized for efficacy and a superior safety profile.
Our technology allows us to fuse cytotoxic cytokines to antibodies to
selectively target disease causing cells and tissues while reducing the
systemic toxicity of the cytokines.